Cai’s team focused on gallbladder cancer (Wang, 2020), and they used three different concentrations of deguelin to treat GBC-SD and SGC-996 gallbladder cancer cell lines, and found that deguelin could inhibit PTEN/PI3K/AKT signaling pathway and reverse epithelial mesenchymal transition (EMT) in vitro, and inhibit the proliferation, migration and invasion of gallbladder cancer cells in a dose-dependent manner. Here, AKT1 is linked to gallbladder cancer.